ArticleBiomolecules & therapeutics2010
Interleukin-4, Oxidative Stress, Vascular Inflammation and Atherosclerosis.
Article in Biomolecules & therapeutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Meta-analysis of the association between interleukin-17 and ischemic cardiovascular disease.BMC cardiovascular disorders · 2024Pooled it
- A Systematic Review of Interleukins as Diagnostic and Prognostic Biomarkers for Peripheral Artery Disease.Biomolecules · 2023Pooled it
- Effect ofInternational journal of food science · 2025Article
- Atheroprotective role of vinpocetine: an old drug with new indication.Inflammopharmacology · 2024Review
- Differential circulating cytokine profiles in acute coronary syndrome versus stable coronary artery disease.Scientific reports · 2024Article
- The anti-inflammatory properties of vinpocetine mediates its therapeutic potential in management of atherosclerosis.Journal of inflammation (London, England) · 2024Review
- Anti-Inflammatory Activity of Pyrazolo[1,5-Molecules (Basel, Switzerland) · 2024Article
- Identification of Biomarkers Associated with Oxidative Stress and Immune Cells in Acute Pancreatitis.Journal of inflammation research · 2024Article
- IL-4 and IL-13 induce equivalent expression of traditional M2 markers and modulation of reactive oxygen species in human macrophages.Scientific reports · 2023Article
- Pump-Less Platform Enables Long-Term Recirculating Perfusion of 3D Printed Tubular Tissues.Advanced healthcare materials · 2023Article
- Immunophenotyping of Monocyte Migration Markers and Therapeutic Effects of Selenium on IL-6 and IL-1β Cytokine Axes of Blood Mononuclear Cells in Preoperative and Postoperative Coronary Artery Disease Patients.International journal of molecular sciences · 2023Article
- Association of IL-4 with pachychoroid neovasculopathy.Scientific reports · 2023Article
- Chronic Community Exposure to Environmental Metal Mixtures Is Associated with Selected Cytokines in the Navajo Birth Cohort Study (NBCS).International journal of environmental research and public health · 2022Article
- Targeting Immune Senescence in Atherosclerosis.International journal of molecular sciences · 2022Review
- Safety and Feasibility Assessment of Repetitive Vascular Occlusion Stimulus (RVOS) Application to Multi-Organ Failure Critically Ill Patients: A Pilot Randomised Controlled Trial.Journal of clinical medicine · 2022Article
- Pyridazinones and Structurally Related Derivatives with Anti-Inflammatory Activity.Molecules (Basel, Switzerland) · 2022Article
- Serum Cytokines Predict the Severity of Coronary Artery Disease Without Acute Myocardial Infarction.Frontiers in cardiovascular medicine · 2022Article
- A StandardizedPlants (Basel, Switzerland) · 2021Article
- Effect of docosahexaenoic acid plus insulin on atherosclerotic human endothelial cells.Journal of inflammation (London, England) · 2021Article
- GAS5 knockdown suppresses inflammation and oxidative stress induced by oxidized low-density lipoprotein in macrophages by sponging miR-135a.Molecular and cellular biochemistry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The pro-oxidative and pro-inflammatory pathways in vascular endothelium have been implicated in the initiation and progression of atherosclerosis. In fact, inflammatory responses in vascular endothelium are primarily regulated through oxidative stress-mediated signaling pathways leading to overexpression of pro-inflammatory mediators. Enhanced expression of cytokines, chemokines and adhesion molecules in endothelial cells and their close interactions facilitate recruiting and adhering blood leukocytes to vessel wall, and subsequently stimulate transendothelial migration, which are thought to be critical early pathologic events in atherogenesis. Although interleukin-4 (IL-4) was traditionally considered as an anti-inflammatory cytokine, recent in vitro and in vivo studies have provided robust evidence that IL-4 exerts pro-inflammatory effects on vascular endothelium and may play a critical role in the development of atherosclerosis. The cellular and molecular mechanisms responsible for IL-4-induced atherosclerosis, however, remain largely unknown. The present review focuses on the distinct sources of IL-4-mediated reactive oxygen species (ROS) generation as well as the pivotal role of ROS in IL-4-induced vascular inflammation. These studies will provide novel insights into a clear delineation of the oxidative mechanisms of IL-4-mediated stimulation of vascular inflammation and subsequent development of atherosclerosis. It will also contribute to novel therapeutic approaches for atherosclerosis specifically targeted against pro-oxidative and pro-inflammatory pathways in vascular endothelium.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.